All News

A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma (HCC), including a host of targeted therapies and various immune checkpoint inhibitors.

In an interview with CURE, DeMichele explains the significance of the I-SPY 2 data, the advantages of Kadcyla versus standard of care and what is on the horizon for the use of Kadcyla in HER2-positive disease.

Cancer is often about quantity when it should be about quality.

The first-line treatment paradigm for lung cancer is shifting.

Thanks to an addition of three biological markers to conventional breast cancer risk models, women can now better determine if they are at high or low risk for developing the disease.

It's not always smooth sailing with breast cancer.

The FDA approved Cabometyx (cabozantinib) for patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy.

The FDA granted Opdivo (nivolumab) a breakthrough therapy designation to treat certain patients with head and neck cancer.

The combination of Yervoy and Opdivo showed a 42 percent improvement in overall survival compared with Yervoy monotherapy for patients with advanced melanoma in a two-year assessment of the phase 2 CheckMate-069 trial.

A phase 3 study presented at the 2016 AACR Annual Meeting showed that Opdivo doubled one-year survival rate for patients with recurrent or metastatic head and neck squamous cell carcinoma.

The FDA granted Keytruda a breakthrough therapy designation after success in early trials. Information from the phase 2 trial will soon be presented.

Signs of worry and hope as seasons slowly change

Opdivo (nivolumab) is showing promise for patients with metastatic melanoma.

Atezolizumab was granted priority review for some patients with metastatic bladder cancer after showing promising results in a phase 2 study.

Cancer blogger Carrie Miller Corey passed away in March, but left behind a son, a legacy and many priceless memories.

CURE spoke with John O. Mascarenhas about advancements in the care of myelofibrosis.

I think about how much I have changed in two years time, and how cancer has changed the trajectory of my life.

We lost a good man to cancer not that long ago but you most certainly didn’t hear about it. He was a teacher, husband, father, mentor, coach and survivor right up to the end.

Gilotrif (afatinib) recently gained approval for some patients with non–small cell lung cancer (NSCLC).

Girls treated for cancer with radiotherapy in their childhood may grow up to have a higher risk of developing breast cancer if they have certain genetic mutations.